Latest News

  • RESEARCH

    30 Jan 2026

    New Metabolic Data Reignite Interest in Liver-Targeted Lipid Drugs

  • PARTNERSHIPS

    20 Jan 2026

    Roche’s 89bio Deal Heats Up the Race for MASH Drugs

  • INSIGHTS

    19 Jan 2026

    A $160M Biotech Bet Points to Obesity Drugs’ Next Test

  • RESEARCH

    16 Jan 2026

    FDA Fast Tracks Dual-Action MASH Drug: Is Momentum Back?

Big Pharma’s Next Obesity Bet Comes in Pill Form

Lilly and Nimbus Therapeutics logos displayed to mark an obesity drug development partnership

PARTNERSHIPS

13 Jan 2026

Drugmakers push oral obesity pills into late trials, aiming to move weight loss care beyond injections and into mass-market medicine

Clinician reviewing laboratory data beside test tubes in medical research setting

RESEARCH

30 Jan 2026

New Metabolic Data Reignite Interest in Liver-Targeted Lipid Drugs

Early clinical data revive a sidelined liver pathway, drawing fresh attention while leaving Phase 2 results as the real test

Illustration of a human liver showing cellular damage linked to metabolic disease

PARTNERSHIPS

20 Jan 2026

Roche’s 89bio Deal Heats Up the Race for MASH Drugs

Roche’s acquisition of 89bio signals rising confidence in late-stage MASH drugs and sharpens competition for metabolic liver disease treat...

Laboratory researcher pipetting samples during obesity drug development research

INSIGHTS

19 Jan 2026

A $160M Biotech Bet Points to Obesity Drugs’ Next Test

A newly funded startup is betting durability, not just weight loss, will define the next era of obesity drugs

Road sign displaying the words Fast Track against a blue sky

RESEARCH

16 Jan 2026

FDA Fast Tracks Dual-Action MASH Drug: Is Momentum Back?

FDA grants two expedited reviews to a dual-action MASH drug, reviving interest in metabolic approaches without signaling a policy overhaul

Lilly and Nimbus Therapeutics logos displayed to mark an obesity drug development partnership

PARTNERSHIPS

13 Jan 2026

Big Pharma’s Next Obesity Bet Comes in Pill Form

Drugmakers push oral obesity pills into late trials, aiming to move weight loss care beyond injections and into mass-market medicine

Eli Lilly corporate headquarters sign outside company office building

INVESTMENT

12 Jan 2026

Lilly’s Ventyx Deal Points to a Future Beyond Injections

Eli Lilly’s $1.2B Ventyx buy shows growing confidence in oral small-molecule drugs aimed at inflammation and long-term metabolic health

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.